Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709043 · ClinicalTrials.gov registry record · Phase 2
Addressing Heavy Alcohol Use Consumption With Kudzu
A Phase 2 study of Alcohol Use Disorder and Sexually Transmitted Diseases, sponsored by Glenn-Milo Santos.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03709043: Completed Phase 2 study of Alcohol Use Disorder and Sexually Transmitted Diseases, sponsored by Glenn-Milo Santos.
NCT03709043 is a Phase 2 study of Alcohol Use Disorder and Sexually Transmitted Diseases that has completed, run by Glenn-Milo Santos. The registered enrollment target is 120 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709043, a Phase 2 study of Alcohol Use Disorder and Sexually Transmitted Diseases, has completed, sponsored by Glenn-Milo Santos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol use and alcohol-associated sexual behaviors among sexually-active, binge-drinking individuals at high risk for HIV infection.
Primary Outcome
Binge-drinking (five or more drinks on a single occasion for men; four or more drinks for women)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Standardized kudzu
- DIAGNOSTIC_TEST Sexually transmitted infection testing:
- BEHAVIORAL Medical Management (MM) counseling for alcohol use:
- DIAGNOSTIC_TEST Urinalysis for novel alcohol biochemical markers for recent alcohol use:
Study Locations (1)
California
- San Francisco Department of Public Health - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2024-06-01 |
| Phase | Phase 2 |
What the finished NCT03709043 record still lists
NCT03709043 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03709043 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03709043 about?
NCT03709043 is a clinical study titled "Addressing Heavy Alcohol Use Consumption With Kudzu". Drinking multiple alcoholic drinks on a single occasion (binge drinking), has many negative health risks but interventions to address this behavior remain limited. This double-blind, placebo-controlled randomized clinical trial will test whether kudzu, an herbal supplement, can reduce heavy alcohol ...
What is the current status of trial NCT03709043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-07-11. Estimated completion is 2024-06-01.
What conditions does trial NCT03709043 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Sexually Transmitted Diseases.
What interventions are being tested in trial NCT03709043?
The interventions under investigation include: Placebo (OTHER), Standardized kudzu (DRUG), Sexually transmitted infection testing: (DIAGNOSTIC_TEST), Medical Management (MM) counseling for alcohol use: (BEHAVIORAL), Urinalysis for novel alcohol biochemical markers for recent alcohol use: (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03709043?
This trial is sponsored by Glenn-Milo Santos, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03709043 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03709043's enrollment target sits among peer trials
120 76th of 184 higher than 108 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI